GLP-1 drugs are generally administered as an injection, and side effects may occur
Although we did not expect SEM to cross the BRB, we anticipated that its retinal effects likely arise from indirect signaling via the CVOs or peripheral pathways, such as the increased vascular permeability associated with this OHT model [20]
This portfolio reflects Lillys strategy of pursuing multiple complementary approaches to metabolic disease: Tirzepatide : Dual GIP/GLP-1 agonist (approved, injectable) Retatrutide : Triple GIP/GLP-1/glucagon agonist (Phase 3, injectable) Orforglipron : Oral GLP-1R agonist (Phase 3, oral) If retatrutide is approved, it could be positioned as a more potent option for patients requiring greater weight loss or those with MASLD, while tirzepatide and orforglipron serve other patient segments
Both the flu and common cold are caused by contagious respiratory viruses, and they share many symptoms
#ObesityCare #GLP1 #Tirzepatide #Semaglutide #WeightRegain #ObesityMedicine #ChronicCare #HealthPolicy #MetabolicHealth If we consider the multiple environmental and psychosocial aspect of weight gain, its not surprising